LAS VEGAS, May 1, 2013 /PRNewswire/ -- PharmaRoth Labs, Inc. (OTCPink: FROI) (the "Company") announced today its name change to PharmaRoth Labs, Inc. will be effective upon the open of trading on May 2, 2013. The Company's common stock will begin trading under the new trading symbol "ROTH".
"We are pleased to announce the effectiveness of our name and trading symbol changes as they now more adequately reflects our focus on the production, marketing, and distribution of Sucanon®," stated the Company's CEO Luis Lopez, "It also completes the entry into the public marketplace and of our reorganized company so our shareholders will be more able to identify us."
Sucanon® is a dietary supplement containing natural ingredients. In certain ex-US countries, it is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers". Pre-clinical and clinical studies conducted ex-US have shown that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® has been approved for prescription sale in China and Peru. Sucanon® is also approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico. Sucanon® will be marketed as a dietary supplement in the US.
For further information regarding Sucanon®, please visit PharmaRoth Labs, Inc. website at www.feroindustries.com.
About PharmaRoth Labs, Inc.
PharmaRoth Labs, Inc. (OTCPink: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For investor relations contact:
Michael Irving - Paramount Advisors, LLC (407) 878-5462
SOURCE PharmaRoth Labs, Inc.